Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence-Reference-Cited by-同舟云学术

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

Published:2018-03-10 Issue:5 Volume:67 Page:649-656
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Gerding Dale N¹,Kelly Ciaran P²,Rahav Galia³,Lee Christine⁴⁵,Dubberke Erik R⁶,Kumar Princy N⁷,Yacyshyn Bruce⁸,Kao Dina⁹,Eves Karen¹⁰,Ellison Misoo C¹¹,Hanson Mary E¹²,Guris Dalya¹⁰,Dorr Mary Beth¹⁰

Affiliation:

1. Department of Veterans Affairs, Edward Hines Jr Veterans Affairs Hospital, Illinois

2. Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

3. Infectious Diseases, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel-Aviv University, Israel

4. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver

5. McMaster University, Hamilton, Ontario, Canada

6. Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri

7. Division of Infectious Diseases and Travel Medicine, Georgetown University School of Medicine, Washington, D.C

8. Division of Digestive Diseases, University of Cincinnati, Ohio

9. Department of Medicine, Division of Gastroenterology, University of Alberta, Edmonton, Canada

10. Clinical Research, Infectious Diseases, Kenilworth, New Jersey

11. Late Development Statistics, Biostatistics, Kenilworth, New Jersey

12. Global Scientific and Medical Publications, Infectious Diseases, Merck & Co, Inc, Kenilworth, New Jersey

Funder

Merck & Co, Inc

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/67/5/649/25496729/ciy171.pdf

Reference23 articles.

1. Gut microbiota and Clostridium difficile infections;Lagier;Hum Microbiome J,2016

2. Fidaxomicin versus vancomycin for Clostridium difficile infection;Louie;N Engl J Med,2011

3. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials;Johnson;Clin Infect Dis,2014

4. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection;Sheitoyan-Pesant;Clin Infect Dis,2016

5. Burden of Clostridium difficile infection in the United States;Lessa;N Engl J Med,2015

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review;World Journal of Gastrointestinal Pharmacology and Therapeutics;2024-09-05

2. De novo design of potent inhibitors of Clostridioides difficile toxin B;2024-08-26

3. Japanese Society for infection prevention and control guide to Clostridioides difficile infection prevention and control;Journal of Infection and Chemotherapy;2024-08

4. More than a new name;The Nurse Practitioner;2024-07-25

5. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI;Infectious Diseases and Therapy;2024-06-28